Trial Profile

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986158 (Primary) ; Nivolumab (Primary)
Indications Advanced breast cancer; Fallopian tube cancer; Haematological malignancies; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Bristol-Myers Squibb

08 Feb 2022 Status changed from active, no longer recruiting to completed.
31 Jul 2021 This trial is discontinued in Belgium (End Date: 22 Dec 2020), according to European Clinical Trials Database record.
09 Apr 2021 This trial is discontinued in Spain (Global End Date: 22 Dec 2020), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com